Canada markets closed

Aprea Therapeutics, Inc. (APRE)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
0.9500-0.0386 (-3.90%)
At close: 04:00PM EDT
0.9800 +0.03 (+3.16%)
After hours: 05:18PM EDT

Aprea Therapeutics, Inc.

535 Boylston St.
Boston, MA 02116
United States

Full Time Employees

Key Executives

NameTitlePayExercisedYear Born
Mr. Christian S. SchadeChairman & CEON/AN/A1961
Dr. Oren Gilad Ph.D.Co-Founder, Pres & DirectorN/AN/A1968
Mr. Scott M. CoianteSr. VP, CFO & Sec.N/AN/A1967
Dr. Gregory A. Korbel Ph.D.Sr. VP & COON/AN/A1976
Dr. Dansu Li Ph.D.Head of TechnologyN/AN/AN/A
Dr. Lars B. Abrahmsen Ph.D.Sr. VP & Chief Scientific OfficerN/AN/A1957
Dr. Rifat Pamukcu M.D.Chief Medical Advisor & DirectorN/AN/A1958
Mr. Hank BreslinHead of Medicinal ChemistryN/AN/AN/A
Dr. Michel Afargan Ph.D.Head of Pharmacology Devel.N/AN/AN/A
Dr. Eyal C. Attar M.D.Sr. VP & Chief Medical OfficerN/AN/A1971
Amounts are as of and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel cancer therapeutics that target DNA damage response pathways. Its lead product candidate is ATRN-119, an oral ATR inhibitor that is in phase 1/2a clinical trial to treat patients with advanced solid tumors. The company's products pipeline also includes ATRN-Backup, an ATR inhibitor; ATRN-W1051 to treat anti-tumor activity; and ATRN-DDRi. Aprea Therapeutics, Inc. is based in Boston, Massachusetts.

Corporate Governance

Aprea Therapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.